Philippos Costa, MD
Clinical FellowDownloadHi-Res Photo
About
Titles
Clinical Fellow
Positions outside Yale
Scientific-Advisor, Medical Oncology, Associação Tumor Desmoide Brasil
Biography
Philippos A. Costa, M.D., is an Oncology fellow at Yale University. He received his medical degree from the Universiade Federal do Vale do Sao Francisco, Brazil, and completed two internal medicine residencies; at the Universidade Federal de Uberlandia and at the University of Miami Miller School of Medicine. He is an expert in Early Developmental Therapeutics as well as Sarcomas, including angiosarcomas, chondrosarcomas, leiomyosarcoma, GIST, and desmoid tumors.
Appointments
Medical Oncology and Hematology
Clinical FellowPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology and Hematology
Education & Training
- Internal Medicine
- University of Miami (2022)
- Internal Medicine
- Universidade Federal de Uberlândia: (2018)
- MD
- Universidade Federal do Vale do São Francisco, Medicine (2016)
Board Certifications
Internal Medicine
- Certification Organization
- ABIM
- Original Certification Date
- 2022
Research
Overview
• Dr. Costa described the association of desmoid tumors with breast implants and the comparative efficacy of different systemic therapies in desmoid tumors
• Along with his colleagues, Dr. Costa described the genetic landscape of angiosarcoma, along with its implications for immunotherapy strategies
• Dr. Costa described how dose escalation of ripretinib can lead to further benefits for GIST patients in a real-world scenario.
Research at a Glance
Yale Co-Authors
Frequent collaborators of Philippos Costa's published research.
Publications Timeline
A big-picture view of Philippos Costa's research output by year.
Andrew Haims, MD
Hari Deshpande, MD
Kelly Olino, MD, FACS
Michael Hurwitz, MD, PhD
22Publications
Publications
2025
Enhancing rare cancer care in developing countries through patient advocacy: insights from the Desmoid Tumor Brazilian Association.
Costa PA, Menezes C, Bianca Lopes David B, Garofalo G, Prudente Barbieri L, Campos F. Enhancing rare cancer care in developing countries through patient advocacy: insights from the Desmoid Tumor Brazilian Association. Ther Adv Med Oncol 2025, 17: 17588359241309827. PMID: 39801613, DOI: 10.1177/17588359241309827.Peer-Reviewed Original Research
2024
Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024 PMID: 39543805, DOI: 10.1002/cncr.35647.Peer-Reviewed Original ResearchAltmetricConceptsProgression-free survivalAnthracycline-containing regimensAnthracycline-based therapyDesmoid tumorsAdverse eventsOne-year progression-free survivalMulti-institutional retrospective analysisAnthracycline-containing regimenCommon grade 1Desmoid tumor patientsGrade 3 eventsAnthracycline-based chemotherapyHand-foot syndromeSecondary end pointsActivity of sorafenibProgressive desmoid tumorsYear of treatmentMedian TTRBaseline characteristicsTumor patientsLocal invasionTreatment responseSorafenibAnthracyclinesEnd pointsReal-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study.
Noujaim J, Gupta AA, Holloway CL, Saleh R, Srikanthan A, Lemieux C, Soroka HP, Tibout P, Turcotte R, Feng X, Abdul Razak AR, Costa P. Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study. Eur J Cancer 2024, 205: 114119. PMID: 38759389, DOI: 10.1016/j.ejca.2024.114119.Peer-Reviewed Original ResearchNeoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma.
Costa PA, Tse DT, Benedetto P. Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma. Oncologist 2024, 29: 263-269. PMID: 38227581, DOI: 10.1093/oncolo/oyad346.Peer-Reviewed Original Research
2023
MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results.
Souza FF, D'Amato G, Jonczak EE, Costa P, Trent JC, Rosenberg AE, Yechieli R, Temple HT, Pattany P, Subhawong TK. MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results. Front Oncol 2023, 13: 1286807. PMID: 38188297, DOI: 10.3389/fonc.2023.1286807.Peer-Reviewed Original ResearchTime to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV.
O'Neil DS, Martei YM, Crew KD, Castillo BS, Costa P, Lim T, Michel A, Rubin E, Goel N, Hurley J, Lopes G, Antoni MH. Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Netw Open 2023, 6: e2346223. PMID: 38051529, DOI: 10.1001/jamanetworkopen.2023.46223.Peer-Reviewed Original Research
2022
Acute pancreatitis from a delayed haemolytic transfusion reaction.
Yan CL, Costa PA, Wu Y. Acute pancreatitis from a delayed haemolytic transfusion reaction. Transfus Med 2022, 32: 522-524. PMID: 36056461, DOI: 10.1111/tme.12912.Peer-Reviewed Case Reports and Technical NotesTreatment of Disseminated Intravenous Leiomyomatosis With ALK Targeting Crizotinib: A Successful Case Report.
Barreto-Coelho P, Rosenberg A, Subhawong T, Costa P, Espejo-Freire AP, Bialick S, Jonczak E, Trent JC, D'Amato GZ. Treatment of Disseminated Intravenous Leiomyomatosis With ALK Targeting Crizotinib: A Successful Case Report. JCO Precision Oncology 2022, 6: e2100336. PMID: 35108034, DOI: 10.1200/PO.21.00336.Peer-Reviewed Case Reports and Technical NotesPanuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate.
Costa PA, Espejo-Freire AP, Fan KC, Albini TA, Pongas G. Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate. Leukemia & Lymphoma 2022, 63: 239-242. PMID: 34514943, DOI: 10.1080/10428194.2021.1978090.Peer-Reviewed Case Reports and Technical NotesPrimary jejunal gastrointestinal stromal tumor in a patient with phakomatosis: a case report of an uncommon source of massive gastrointestinal hemorrhage
Minjares RO, Aguirre LE, Costa PA, Montoya-Cerrillo DM, Goldberg DS. Primary Jejunal GIST in a Patient with Phakomatosis: An Atypical Source of Massive Gastrointestinal Hemorrhage Associated with RASopathy. Gastrointestinal Stromal Tumor 2022. doi: 10.21037/gist-21-13Peer-Reviewed Case Reports and Technical Notes
Academic Achievements & Community Involvement
activity GIST Journal
Peer Review Groups and Grant Study SectionsReviewerDetails07/01/2021 - Presentactivity Managed Health Care
Media PresenceResearcherDetailsFeatured in magazine article entitled “Black Lung Cancer Patients May Be Missing Out On Era of Targeted Therapy” based on the work “Prevalence of Targetable Mutations in Black Patients"2022 - Presentactivity American Society of Clinical Oncology (ASCO)
Professional OrganizationsMemberDetails02/01/2018 - Presentactivity American College of Physicians (ACP)
Professional OrganizationsMemberDetails2018 - Presentactivity Sociedade Brasileira de Oncologia Clínica (SBOC)
Professional OrganizationsMemberDetails2018 - Present
News
News
Get In Touch
Contacts
Mailing Address
Medical Oncology
330 Cedar Street, Room WWW201
New Haven, Connecticut 06520
United States